Edgar Filing: GONELLA JACQUES - Form 4

GONELLA	A JACQUES									
Form 4	200									
May 18, 20								OMB A	APPROVAL	
FOR	VI 4 UNITED	STATES		CURITIES AND EXCHANGE COMMISSION					3235-0287	
Check		Washington, D.C. 20549					Number: Expires:	January 31,		
if no lo subject Section Form 4	to SIAIE 116.	MENT OI	OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES						2005 average urs per	
Form 5 obligat may co	Filed put	(a) of the l	Public U	Jtility Hol	lding Co		nge Act of 1934, of 1935 or Sectio 940	response	0.5	
(Print or Type	e Responses)									
1. Name and Address of Reporting Person <u>*</u> GONELLA JACQUES			2. Issuer Name and Ticker or Trading Symbol ANTARES PHARMA, INC. [AIS]			5. Relationship of Reporting Person(s) to Issuer				
(Last)	(First) (Middle)				NC. [AIS]	(Cheo	ck all applicabl	le)	
(Last) (First) (Middle) C/O ANTARES PHARMA, INC., 250 PHILLIPS BLVD, SUITE 290			3. Date of Earliest Transaction (Month/Day/Year) 05/14/2009				X_ DirectorX_ 10% Owner Officer (give title below) Other (specify below)			
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
EWING, N	NJ 08618						Form filed by M Person			
(City)	(State)	(Zip)	Tat	ole I - Non-	Derivative	Securities A	cquired, Disposed o	f, or Beneficia	ally Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any	Date, if	3. Transactic Code (Instr. 8) Code V		(A) or of (D)	SecuritiesIBeneficially(Owned(6. Ownership Form: Direct D) or Indirect I) Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: R	eport on a separate line	e for each cl	ass of sec	urities bene	ficially ow	ned directly o	or indirectly.			
					inforr requi	nation cont red to respo ays a currer	spond to the collec ained in this form ond unless the for ntly valid OMB cor	are not m	SEC 1474 (9-02)	
	Tab					sposed of, or convertible s	Beneficially Owned securities)			
1. Title of Derivative		saction Date /Day/Year)			4. Transact	5. Number iorDerivative			7. Title and Amount of Underlying Securities	

Edgar Filing: GONELLA JACQUES - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A or Disposed (D) (Instr. 3, 4, and 5)		(Month/Day/	Month/Day/Year)		(Instr. 3 and 4)	
				Code V	(A) ((D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 0.53	05/14/2009		А	30,000 (1)		(2)	05/13/2019	Common Stock	30,000	
Repo	rting Ov	vners									
Reporting Owner Name / Address			Relatio	nships							

	Director	10% Owner	Officer	Other
GONELLA JACQUES C/O ANTARES PHARMA, INC. 250 PHILLIPS BLVD, SUITE 290 EWING, NJ 08618	Х	Х		
Signatures				

Robert F. Apple as attorney-in-fact for Jacques 05/18/2009 Gonella **Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Represents grant of options to purchase shares of common stock, par value \$0.01 per share, issued under the Antares Pharma, Inc. (1) 2008 Equity Compensation Plan.
- (2) The option vests in four equal quarterly installments.
- (3) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

C